| Summary: | Ovarian cancer is a leading cause of death from gynecologic malignancies. Most ovarian carcinomas are diagnosed in an advanced stage. Surgical treatment promotes a high response rate combined with chemotherapy. However, two-thirds of patients experience a relapse, followed by a development of chemoresistance, and, subsequently, death. The biological diversity of individual types of ovarian carcinoma is so varied, that a single treatment regimen can not be considered as a fitting treatment for all patients. Various studies focus on the individualisation of cancer treatment. This study targets the in vitro sensitivity testing in ovarian carcinoma cells on cytostatics using the MTT test. We presume that this method could be utilised in clinical decision-making process. Between the years 2006 and 2010, we have acquired tumor tissue and malignant ascites from a total of 55 patients enrolled in our study and analyzed those samples in vitro for chemosensitivity / chemoresistance using the MTT test. The aim of this research work was to asses chemosensitivity of ovarian carcinoma cells and compare these results with clinical parameters. Carcinoma cells displayed in vitro chemosensitivity to cisplatin in 67% of patients. Tumor cells of 22% patients proved to be sensitive to carboplatin and 16% to paclitaxel....
|
|---|
